Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
Like
Facebook
Tweet
General Session
Session III - Strategies to Address Barriers and Optimize Outcomes in Luminal Crohn’s Disease
Friday, July 21, 2023
5:00 PM – 5:45 PM
.
This session is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A.
Learning Objectives:
Describe the prevalence and burden of luminal CD and barriers to effective treatment
Evaluate the most recent safety and efficacy data associated with current and emerging therapies, including novel formulations for biologic delivery
Assess the most current clinical guidelines for luminal CD and implement strategies for improved management and treatment outcomes